Vaccines and antibodies in the prevention and treatment of sepsis

Infectious Disease Clinics of North America

Volumn 13, Issue 2, 1999, Pages 355-369

  Bhattacharjee, A K ^a   Cross, A S ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; ENDOTOXIN ANTIBODY; EPITOPE; GLYCOLIPID; LIPID A; POLYSACCHARIDE; VACCINE;

HUMAN; REVIEW; SEPSIS; STRUCTURE ACTIVITY RELATION;

EID: 0032999933     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70079-9     Document Type: Article

References (63)

1. Anonymous Increase in national hospital discharge survey rates for septicemia— United States, 1979–87 MMWR Morb Mortal Wkly Rep 39 1990 31
2. Bahrami S. Yao Y.-M. G. Leichtfried Monoclonal antibody to endotoxin attenuates hemorrhage-induced lung injury and mortality in rats Crit Care Med 25 1997 1030
3. S. Bailat D. Heumann D. LeRoy Similarities and disparities between core-specific and O-side-chain–specific antilipopolysachairde monoclonal antibodies in models of endotoxemia and bacteremia in mice Infect Immun 65 1997 811
4. J.D. Baumgartner D. Heumann T. Calandra Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5 J Infect Dis 163 1991 769
5. J.D. Baumgartner Immunotherapy with antibodies to core lipopolysaccharide: A critical appraisal Infect Dis Clin North Am 5 1991 753
6. J.D. Baumgartner D. Heumann J. Gerain Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6. Comparison of O-side-chain–specific antibodies with core LPS antibodies J Exp Med 171 1990 889
7. Bennett I.L. Jr Approaches to the mechanisms of endotoxin action Braun W. Landy M. Bacterial Endotoxins: Proceedings of a Symposium held at the Institute of Microbiology of Rutgers, the State University 1964 Institute of Microbiology, Rutgers, the State University New Brunswick xiii xxvi
8. E. Bennett-Guerrero L. Ayuso C. Hamilton-Davies Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery JAMA 277 1997 646
9. A.K. Bhattacharjee A.S. Cross S.M. Opal New Trends in Escherichia coli O111:B4 J5 Mutant (Rc chemotype) Vaccine development for use in gram-negative bacillary sepsis Morrison D.C. Ryan J.L. Novel Therapeutic Strategies in the Treatment of Sepsis 1996 Marcel Dekker New York 31
10. A.K. Bhattacharjee S.M. Opal J.E. Palardy Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis J Infect Dis 170 1994 622
11. A.K. Bhattacharjee S.M. Opal R. Taylor A non-covalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia J Infect Dis 173 1996 1157
12. L. Brade R. Engel W.J. Christ A nonsubstituted primary hydroxyl group in position 6′ of free lipid A is required for binding of lipid A monoclonal antibodies Infect Immun 65 1997 3961
13. A.E. Braude J.L. Jones H. Douglas The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis J Immunol 90 1963 297
14. J.G. Brock-Utne S.L. Gaffin M.T. Wells Endotoxemia in exhausted runners after a long-distance race S Afr Med J 73 1988 533
15. T. Calandra M.P. Glauser J. Schellekens Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial J Infect Dis 158 1988 312
16. W.N. Campbell E. Hendrix Cryz S.J. Jr Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomonas O-polysaccharide conjugate vaccine administered to acute trauma victims Clin Infect Dis 23 1996 179
17. J. Cohen R.H. Moore Al Hashimi S. Antibody titers to a rough mutant strain of Escherichia coli in patients undergoing allogeneic bone marrow transplantation. Evidence for a protective effect against graft-versus-host disease Lancet 1 1987 8
18. A. Cometta J.D. Baumgartner Lee M.L. the IVIG study group Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection N Engl J Med 237 1992 234
19. A.S. Cross S. Opal Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? Journal of Endotoxin Research 1 1994 57
20. P.A. Dale D.P. McQuillen S. Gulati Human vaccination with Escherichia coli J5 mutant induces cross-reactive bactericidal antibody against Neisseria gonorrhoeae lipooligosaccharide J Infect Dis 166 1992 316
21. T.R. DeKievit J.S. Lam Monoclonal antibodies that distinguish inner core, outer core and lipid A regions of Pseudomonas aeruginosa lipopolysaccharide J Bacteriol 176 1994 7129
22. DeMaria A. Jr M.A. Johns H. Berberich Immunization with rough mutants of Salmonella minnesota : Initial studies in human subjects J Infect Dis 158 1988 301
23. F.E. DiPadova H. Brade G.R. Barclay A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides Infect Immun 61 1993 3863
24. S.T. Donta P. Peduzzi A.S. Cross Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections J Infect Dis 174 1996 537
25. A. Fomsgaard L. Baek J.S. Fomsgaard Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors Scand J Infect Dis 21 1989 697
26. Y. Fujihara W.C. Bogard M.G. Lei Monoclonal anti-lipid A IgM antibodies HA-1A and E5 recognize distinct epitopes on lipopolysaccharides and lipid A J Infect Dis 168 1993 1429
27. P. Gathiram M.T. Wells J.G. Brock-Utne Antilipopolysacchairde improves survival in primates subjected to heat stroke Circulatory Shock 23 1987 157
28. H.F. Geerdes D. Ziegler H. Lode Septicemia in 98 patients at a university hospital in Berlin: Prospective studies during 4 selected years between 1979 and 1989 J Infect Dis 15 1992 991
29. A.S. Goldie K.C.H. Fearon Ross J.A. the Sepsis Intervention Group Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome JAMA 274 1995 172
30. R.L. Greenman R.M.H. Schein M.A. Martin A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis JAMA 266 1991 1097
31. J.B. Haug S. Harthug T. Kalager Bloodstream infections at a Norwegian university hospital: 1974–1979 and 1988–1989: Changing etiology, clinical features, and outcome Clin Infect Dis 19 1994 246
32. O. Holst H. Brade Chemical structure of the core region of lipopolysaccharides Morrison D.C. Ryan J.L. Bacterial Endotoxic Lipopolysaccharides, vol I 1992 Molecular Biochemistry and Cellular Biology. CRC Press Boca Raton, FL 135
33. W.N.M. Hustinx K. Kraaijeveld A.I.M. Hoepelman Cross-protection by anti-core glycolipid antibodies: Evidence from animal experiments J Antimicrob Chemother 40 1997 475
34. W.N.M. Hustinx B.J.B. Trouw T. Harmsen Evaluation of protection by two endotoxin-neutralizing IgM monoclonal antibodies in different peritonitis models J Antimicrob Chemother 40 1997 567
35. J5 Study Group Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study J Infect Dis 165 1992 695
36. P.E. Jansson A.A. Lindberg B. Lindberg Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae Eur J Biochem 115 1981 571
37. O. Luderitz A.M. Staub O. Westphal Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae Bacteriological Review 30 1966 192
38. C. Lugowski W. Jachymek T. Niedziela Serological characterization of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid FEMS Immunol Med Microbiol 16 1996 21
39. C. Lugowski T. Niedziela W. Jachymek Anti-endotoxin antibodies directed against Escherichia coli R1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity FEMS Immunol Med Microbiol 16 1996 31
40. H. Masoud I. Sadovskaya De Kievit T.R. Structural elucidation of the lipopolysaccharide core region of the O-chain deficient mutant strain A28 from Pseudomonas aeruginosa serotype O6 (International Antigenic Typing Scheme) J Bacteriol 177 1995 6718
41. W.R. McCabe Immunization with R mutants of S. minnesota . I. Protection against challenge with heterologous gram-negative bacilli J Immunol 108 1972 601
42. K.M. Miner C.L. Manyak E. Williams Characterization of murine monoclonal antibodies to Escherichia coli J5 Infect Immun 52 1986 56
43. S. Muller-Loennies O. Holst H. Brade Chemical structure of the core region of Escherichia coli J-5 lipopolysaccharide Eur J Biochem 224 1994 751
44. L.M. Mutharia G. Crockford W.C. Bogard Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: Cross-reaction with other gram-negative bacterial species Infect Immun 45 1984 631
45. M.J. Nelles C.A. Niswander Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria Infect Immun 46 1984 677
46. M. Nys P. Darnas L. Joassin Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome Ann Surg 217 1993 300
47. M.J. Osborn Biosynthesis and structure of the core region of the lipopolysaccharide of Salmonella typhimurium Ann N Y Acad Sci 133 1966 375
48. T.M. Perl L. Dvorak T. Hwang Long-term survival and function after suspected gram-negative sepsis JAMA 274 1995 339
49. M. Pollack A.I. Huang R.K. Prescott Enhanced survival in Pseudomonas seruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core J Clin Invest 72 1983 1874
50. M. Pollack J.K.S. Chia N.L. Koles Specificity and cross-reactivity of monoclonal antibodies reactive with core and lipid A regions of bacterial lipopolysaccharide J Infect Dis 159 1989 168
51. W.G. Powderly G. Pier R.B. Markham In vitro T cell-mediated killing of Pseudomonas aeruginosa . IV. Nonresponsiveness of polysaccharide-immunized BALB/c mice is attributable to vinblastine-sensitive suppressor T cells J Immunol 137 1986 2025
52. A.A. Quartin R.M.H. Schein Kett D.H. the DVA Systemic Sepsis Cooperative Studies Group Magnitude and duration of the effect of sepsis on survival JAMA 277 1997 1058
53. C.R.H. Raetz The enzymatic synthesis of lipid A: Molecular structure and biologic function of monosaccharide precursors Review of Infectious Diseases 6 1984 463
54. I. Schedel U. Dreikhausen B. Nentwig Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial Crit Care Med 19 1991 1104
55. T.A. Schwartzer D.V. Alcid V. Numsuwan Characterization of the human antibody response to an Escherichia coli O111:B4 (J5) vaccine J Infect Dis 158 1988 1135
56. M. Susskind L. Brade H. Brade Identification of a novel heptoglycan of 1–2-linked D-glycero-D-manno-heptopyranose: Chemical and antigenic structure of lipopolysaccharides from Klebsiella pneumoniae ssp pneumoniae rough strain R20 (O1:K20) J Biol Chem 273 1998 7006
57. H. Takada S. Kotuni Structure function relationships of lipid A Morrison D.C. Ryan J.L. Bacterial Endotoxic Lipopolysaccharides 1992 CRC Press Boca Raton, FL 107
58. M. Trautman K. Vogt C. Hammack A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides Infect Immun 62 1994 1282
59. 60Co irradiated primates: A preliminary report Aviat Space Environ Med 61 1990 802
60. R.G.J. Westendorp J.A.M. Langermans de Bel C.E. Release of tumor necrosis factor: An innate host characteristic that may contribute to the outcome of meningococcal sepsis J Infect Dis 171 1995 1057
61. S.I. Yokota T. Masazumi J. Chiba Variable cross-reactivity of Pseudomonas aeruginosa lipopolysaccharide-core-specific monoclonal antibodies and its possible relationship with serotype Journal of General Microbiology 138 1992 289
62. E.J. Ziegler J.A. McCutchan J. Fierer Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli N Engl J Med 307 1982 1225
63. Ziegler E.J. Fisher C.J. Jr Sprung C.L. the HA-1A Sepsis Study Group Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial N Engl J Med 325 1991 429